The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology/Oncology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Sun, 07 Jun 2026 17:46:17 GMT 2026 NEJM Group en-us 1440 Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing. https://www.nejm.org/doi/full/10.1056/NEJMp2516090?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2516090 Harsimar K. Ahuja, David S. Jones, Winfred W. Williams 2026-06-06 Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. https://www.nejm.org/doi/full/10.1056/NEJMoa2510223?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2510223 Gail J. Roboz, Amer M. Zeidan, Gabriel N. Mannis, Pau Montesinos, Montserrat Arnan, Michael R. Savona, Olatoyosi Odenike, James K. McCloskey, Harshad V. Amin, Amir T. Fathi, Teresa Bernal del Castillo, Gabriela Rodríguez-Macías, Jane L. Liesveld, Annie P. Im, Jan Cerny, Teresa C. Gentile, Aram Oganesian, Danna Chan, Yubing Wan, Margit Dijkstra, Harold N. Keer, Elizabeth A. Griffiths, Courtney D. DiNardo 2026-06-04 All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia A study dissects the way in which fasting or a fasting-mimicking diet augments the effect of hormonal therapy in a mouse model of breast cancer. https://www.nejm.org/doi/full/10.1056/NEJMcibr2600647?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2600647 Nima Sharifi 2026-06-04 Fasting, Glucocorticoids, and Breast Cancer In a patient with recurrent ameloblastoma, zolucatetide (formerly FOG-001) produced an ongoing partial response at 40 weeks, with resolution of solid tumor and cerebral edema. Elevated liver-enzyme levels were noted. https://www.nejm.org/doi/full/10.1056/NEJMc2517783?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2517783 Samuel J. Klempner, Moh’d Khushman, Kyriakos P. Papadopoulos, Meredith P. Pelster, Jordi A. Rodon, Rona Yaeger, Shivaani Kummar, Sunil Sharma, David Bajor, Dennis Hsu, Ranjodh S. Dhami, Bayan Alzumaili, Jeremy D. Kratz, Varun Monga, Alexander Philipovskiy, Jorge Ramos, Amber Wells, Marie H. Nguyen, Jonathan B. Hurov, Michael Cecchini 2026-06-04 Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used. https://www.nejm.org/doi/full/10.1056/NEJMc2517274?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2517274 Kathryn Maitland, Maurice Okao, Melissa D. Conrad, Tonny Etwop, Modester Akite, Emmanuel Oguda, Florence Alaroker, Denis Aromut, Rita Muhindo, Sophie Uyoga, Peter Olupot-Olupot, Christabel Mogaka, Roisin Connon, Thomas Katairo, Martin Okitwi, Jessica Briggs, Diana M. Gibb, Nicholas P.J. Day, Nicholas J. White, Thomas N. Williams, Arjen M. Dondorp, A. Sarah Walker, Elizabeth C. George, Philip J. Rosenthal, for the SMAART-CHARISMA group† 2026-06-03 Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2601337?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601337 Emanuel Della-Torre, Matthew C. Baker, Wen Zhang, Cory A. Perugino, Guy Katz, Yoshiya Tanaka, Arezou Khosroshahi, Alexander Kleger, Nicolas Schleinitz, Fernando Martinez-Valle, Hendrik Schulze-Koops, Shingo Nakayamada, Vinciane Rebours, Kazuichi Okazaki, Lingli Dong, Mollie Carruthers, Luke Y.C. Chen, Luca Frulloni, Alireza Meysami, Hiroki Takahashi, Mitsuhiro Kawano, Yanying Liu, Takako Saeki, Mikael Ebbo, Tobias Alexander, Andrés González García, Omer Karadag, Maria Maślińska, Shauna M. Quinn, Allen Poma, Audrey Wells, Thomas J. Greene, John H. Stone, Emma L. Culver, the INDIGO Trial Investigators* 2026-06-02 Obexelimab for the Treatment of IgG4-Related Disease IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1 https://www.nejm.org/doi/full/10.1056/NEJMe2605617?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605617 Thomas Dörner 2026-06-02 Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin, the RASolute 302 Trial Investigators* 2026-05-31 Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2603878?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603878 Mary-Ellen Taplin, Martin Gleave, Neal D. Shore, Angela Lopez-Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Paul L. Nguyen, Ronaldo Damião, Toshiyuki Kamoto, Ashley Ross, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Álvaro Juárez Soto, Huihui Ye, Geoffrey Gotto, Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Branko Miladinovic, Sharon A. McCarthy, Christopher P. Evans, Adam S. Kibel, the PROTEUS Investigators* 2026-05-31 Perioperative Apalutamide in High-Risk Localized Prostate Cancer Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. https://www.nejm.org/doi/full/10.1056/NEJMoa2602628?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602628 Yi-Long Wu, Maximilian Hochmair, Yi Yang, Xue-Ning Yang, Masahiro Tsuboi, Luis Paz-Ares, James Chih-Hsin Yang, Lin Wu, Hye Ryun Kim, Damian T. Rieke, Melissa Johnson, Benjamin Besse, Nivedita Sharma, Patricia Maeda, Patrick Peterson, Boris Kin Lin, Bente Frimodt-Moller, Jonathan Goldman, Alexander Drilon, the LIBRETTO-432 Trial Investigators† 2026-05-31 Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... https://www.nejm.org/doi/full/10.1056/NEJMe2606250?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606250 Emmanuel S. Antonarakis 2026-05-31 A Watershed Moment in the Perioperative Treatment of Prostate Cancer In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. https://www.nejm.org/doi/full/10.1056/NEJMoa2604126?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604126 Neeraj Agarwal, Nobuaki Matsubara, Arun A. Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D. Shore, Timuçin Çil, Christof Vulsteke, Hsiao-Jen Chung, Stefanie Zschäbitz, A. Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim Fizazi 2026-05-30 PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated... https://www.nejm.org/doi/full/10.1056/NEJMe2605582?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605582 Rana R. McKay 2026-05-30 Precision Intensification in Metastatic Prostate Cancer In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. https://www.nejm.org/doi/full/10.1056/NEJMoa2603870?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603870 Cyrille Touzeau, Roberto Mina, Hang Quach, Vania Hungria, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra Chaulagain, Meletios Athanasios Dimopoulos, Nizar J. Bahlis, Senem Maral, Niels W.C.J. van de Donk, Jayr Schmidt Filho, Khalid Saja, Raphael Teipel, Miki Ando, Wilfried Roeloffzen, Ombretta Annibali, Bradley Augustson, Cirino Botta, Michel Delforge, Emmanuelle Bourgeois, Gabriele Buda, Marek Hus, Aurore Perrot, Meir Preis, Meral Beksac, Ludek Pour, Sarah Farmer, Marta Nunes, Albert Oriol, Thomas Melchardt, Yu Hu, Max Flogegård, Dai Wang, Lixia Pei, Susan Wroblewski, Ingrid M. Ariës, Natalia A. Quijano Cardé, Tatiana Perova, Tertia de Jager, Tzu-Min Yeh, Veronique Vanquickelberghe, Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, Ola Landgren, the MajesTEC-9 Trial Investigators* 2026-05-29 Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. https://www.nejm.org/doi/full/10.1056/NEJMoa2604461?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604461 Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine A. Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro Jr., Li Zheng, John V. Heymach, the WU-KONG28 Investigators* 2026-05-29 First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations The treatment landscape of multiple myeloma has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology, refined patient stratification, the integration of new prognostic biomarkers, and sustained therapeutic innovation. Today, most patients receive proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies as frontline... https://www.nejm.org/doi/full/10.1056/NEJMe2605404?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605404 María-Victoria Mateos 2026-05-29 Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2517729?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2517729 Kohei Shitara, Elena Elimova, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer Ajani, Norhidayu Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Jun Zhao, Cinta Hierro, Andrew Kiberu, Filip Van Herpe, Yuanyuan Bao, Hanze Zhang, Lin Yang, Vincent Li, Elaina M. Gartner, Ye Chen, Jonathan Grim, Sun Young Rha, Lin Shen, the HERIZON-GEA-01 Investigators* 2026-05-28 Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer Ugandan children with sickle cell anemia who received 10 years of hydroxyurea therapy had sustained laboratory and clinical benefits, improved growth, and few toxic effects. https://www.nejm.org/doi/full/10.1056/NEJMc2603063?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2603063 Russell E. Ware, Robert O. Opoka, Teresa Latham, Phillip Kasirye, Priscilla Kasembo, Heather Hume, Isaac Birungi, Norah Kadde, Bill Wambaka, Maria Nakafeero, Andrea L. Conroy, George Tomlinson, Adam Lane, Chandy John 2026-05-28 Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia Two patients with inborn errors of immunity and progressive multifocal leukoencephalopathy received polyomavirus-specific T cells, followed by allogeneic hematopoietic transplantation with good neurologic outcomes. https://www.nejm.org/doi/full/10.1056/NEJMc2514186?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2514186 Corina E. Gonzalez, Anita Fletcher, Tonya L. Jenkins, Sara Zahraeifard, Rose Peterson, Milo Taylor, Christine Jones, Amanda Urban, Daniele Avila, Mauricio Campillay, Jamie Wilhelm, Ariane Soldatos, Jens Kuhle, Poorva Jain, Sydney Corey, Jenna R.E. Bergerson, Daniel S. Reich, Steven Highfill, David Stroncek, Anh Dinh, Stefania Pittaluga, Heidi H. Kong, Helen C. Su, Luigi D. Notarangelo, Sung-Yun Pai, Michael Grimley, Alexandra F. Freeman, Irene Cortese 2026-05-28 Resolution of PML after Treatment with Virus-Specific T Cells and HCT Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. https://www.nejm.org/doi/full/10.1056/NEJMoa2602167?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602167 Jason L. Sperry, Francis X. Guyette, Bryan A. Cotton, James F. Luther, Richard B. Utarnachitt, Matthew E. Kutcher, Brian J. Daley, Allan B. Peetz, Mayur B. Patel, Michael D. Goodman, Jeffrey A. Claridge, Nimitt Patel, Brian G. Harbrecht, Zain G. Hashmi, Ryan Zarychanski, Matthew D. Neal, Mark H. Yazer, Christian Martin-Gill, Laura E. Vincent, Ashley M. Harner, David E. Meyer, Andrew J. Latimer, Bryce R. Robinson, Catherine L. McKnight, William R. Hinckley, Keith R. Miller, Jan O. Jansen, Douglas Martin, Erin E. Fox, Bedda L. Rosario-Rivera, Stephen R. Wisniewski, the TOWAR Study Group* 2026-05-18 Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage